

1 **Slow waning of antibodies following a third dose of BNT162b2 in adults who had**  
2 **previously received two doses of inactivated vaccine**

3

4 Benjamin J. Cowling<sup>1,2</sup>, Samuel M. S. Cheng<sup>1</sup>, Mario Martín-Sánchez<sup>1</sup>, Niki Y. M. Au<sup>1</sup>, Karl  
5 C. K. Chan<sup>1</sup>, John K. C. Li<sup>1</sup>, Leo L. H. Luk<sup>1</sup>, Leo C. H. Tsang<sup>1</sup>, Dennis K. M. Ip<sup>1</sup>, Leo L. M.  
6 Poon<sup>1,3,4</sup>, Gabriel M. Leung<sup>1,2</sup>, J. S. Malik Peiris<sup>†1,3,4</sup>, Nancy H. L. Leung<sup>†1,2</sup>

7

8 <sup>†</sup>Joint senior authors with equal contribution

9

10 **Affiliations:**

- 11 1. WHO Collaborating Centre for Infectious Disease Epidemiology and Control, School of  
12 Public Health, LKS Faculty of Medicine, The University of Hong Kong; Hong Kong Special  
13 Administrative Region, China.
- 14 2. Laboratory of Data Discovery for Health; Hong Kong Science and Technology Park, Hong  
15 Kong Special Administrative Region, China.
- 16 3. HKU-Pasteur Research Pole, School of Public Health, Li Ka Shing Faculty of Medicine,  
17 The University of Hong Kong; Hong Kong Special Administrative Region, China.
- 18 4. Centre for Immunology and Infection; Hong Kong Science and Technology Park, Hong  
19 Kong Special Administrative Region, China.

20

21 **Corresponding author:**

22 Benjamin Cowling, WHO Collaborating Centre for Infectious Disease Epidemiology and  
23 Control, School of Public Health, LKS Faculty of Medicine, The University of Hong Kong;  
24 Hong Kong Special Administrative Region, China. [bcowling@hku.hk](mailto:bcowling@hku.hk)

25

26 Running head: Robust immunity after BNT162b2 booster

27 Word count (abstract): 250

28 Word count (main text): 2175

29

30 **ABSTRACT**

31 **Introduction:** Third doses of COVID-19 vaccination provide an important boost to  
32 immunity, reducing the risk of symptomatic infection and the risk of severe disease. Third  
33 doses have been particularly important for improving protection against variants. However,  
34 waning of clinical protection particularly against Omicron has been noted after receipt of  
35 third doses.

36 **Methods:** We administered BNT162b2 as a third dose to adults aged  $\geq 30$  years who had  
37 previously received two doses of inactivated vaccination. We collected blood before the third  
38 dose and again after one month and six months, and tested sera using a spike receptor binding  
39 domain IgG enzyme-linked immunosorbent assay, a surrogate virus neutralization test, and  
40 live virus plaque reduction neutralization assay against ancestral virus and Omicron BA.2.

41 **Results:** We administered BNT162b2 as a third dose to 314 adults. We found robust  
42 antibody responses to the ancestral strain at six months after receipt of BNT162b2. Antibody  
43 responses to Omicron BA.2 were weaker after the third dose and had declined to a low level  
44 by six months. From a small number of participants we observed that natural infection or a  
45 fourth dose of vaccination generated similar antibody levels against ancestral virus, but  
46 infection generated higher antibody level against Omicron BA.2 than vaccination, suggesting  
47 a potential advantage in the breadth of antibody response from hybrid immunity.

48 **Conclusions:** While antibody levels against the ancestral strain remained robust at six  
49 months after the third dose, antibody levels against Omicron BA.2 had fallen to low levels  
50 suggesting the potential benefits of a fourth dose.

51

## 52 INTRODUCTION

53 Third doses of COVID-19 vaccination provide an important boost to immunity, reducing the  
54 risk of symptomatic infection [1, 2] and the risk of severe disease [2, 3]. Third doses have  
55 been particularly important for improving protection against variants. However, waning  
56 clinical protection particularly against Omicron was noted after receipt of third doses [4, 5],  
57 with fourth doses then providing additional protection [6, 7].

58

59 In recipients of two initial doses of inactivated COVID-19 vaccines, we and others have  
60 shown that a third “booster” dose of BNT162b2 (BioNTech/Pfizer/Fosun Pharma) confers a  
61 very strong antibody response both against the ancestral strain and the Omicron variant [8-  
62 10]. Here, we explore the persistence of antibody titers up to 6 months after a third dose of  
63 BNT162b2 in this regimen.

64

## 65 METHODS

### 66 *Study design*

67 We conducted an open-label single-arm trial to measure the antibody responses to a third  
68 dose of BNT162b2 in adults  $\geq 30$  years old who previously received two doses of an  
69 inactivated COVID-19 vaccine with the second inactivated vaccine dose at least 90 days prior  
70 to enrolment [8]. The BNT162b2 vaccine and the inactivated vaccine CoronaVac (Sinovac)  
71 were both approved for use in Hong Kong in early 2021, while an alternative inactivated  
72 vaccine BIBP (Sinopharm) has been available since early 2021 in mainland China and some  
73 other countries. We enrolled participants from October through December 2021. Participants  
74 were not eligible if they had received any other COVID-19 vaccination apart from the two  
75 doses of inactivated vaccination, if they had a history of laboratory-confirmed COVID-19  
76 infection, if they met a contraindication for BNT162b2, were receiving immuno-modulatory

77 medications, or were females who were pregnant or intending to become pregnant in the  
78 coming 3 months [8].

79

80 Each participant provided a serum sample at Day 0 prior to receipt of BNT162b2, and then  
81 further serum samples on Day 28 ( $\pm 7$  days) and Day 182 ( $\pm 30$  days), with a final sample  
82 planned on Day 365. Participants were provided with a gift voucher of HK\$100 (US\$13) at  
83 the blood draws on Days 28, 182 and 365. We collected information at baseline on  
84 demographics, health status including vaccinations received, and self-reported COVID-19  
85 infection history. We updated this information at the Day 182 visit including information on  
86 any infections that had occurred between Day 28 and Day 182.

87

### 88 ***Ethical approval***

89 All participants provided written informed consent. The study was approved by the  
90 Institutional Review Board of the University of Hong Kong. The study is registered on  
91 Clinicaltrials.gov (NCT05057182).

92

### 93 ***Laboratory methods***

94 We used a SARS-CoV-2 Spike receptor binding domain IgG enzyme-linked immunosorbent  
95 assay (ELISA) for the ancestral strain as previously described [11]. 96-well ELISA plates  
96 (Nunc MaxiSorp, Thermo Fisher Scientific) were coated overnight with 100 ng/well of the  
97 purified recombinant RBD protein in PBS buffer. The plates were then blocked by 100  $\mu$ l of  
98 Chonblock blocking buffer (Chondrex Inc, Redmond, US) per well, and were incubated at  
99 room temperature for 2 hours. Each serum sample was tested at a dilution of 1:100 in  
100 Chonblock blocking buffer in duplicate. They were added and were incubated for 2 hours at  
101 37°C. After extensive washing with PBS containing 0.1% Tween 20, horseradish peroxidase

102 (HRP)-conjugated goat anti-human IgG (1:5,000, GE Healthcare) was added and incubated  
103 for 1 hour at 37°C. The ELISA plates were then washed again with PBS containing 0.1%  
104 Tween 20. Subsequently, 100 µL of HRP substrate (Ncm TMB One; New Cell and Molecular  
105 Biotech Co. Ltd, Suzhou, China) was added into each well. After 15 minutes incubation, the  
106 reaction was stopped by adding 50 µL of 2 M H<sub>2</sub>SO<sub>4</sub> solution and analyzed on a microplate  
107 reader at 450 nm wavelength. Optical density above 0.5 was counted as positive.

108

109 SARS-CoV-2 surrogate virus neutralization test (sVNT) kits (Cat. No.: L00847-A) were  
110 ordered from GenScript, Inc., NJ, USA. The tests were performed according to the  
111 manufacturer's standard protocol. 10 times dilution were performed for samples, positive and  
112 negative controls. They were then mixed with equal volume of horseradish peroxidase (HRP)  
113 conjugated SARS-CoV-2 spike receptor binding domain (RBD) (6 ng). The mixture was  
114 incubated at 37°C for 30 min. After incubation, 100ul of the mixture was added to  
115 corresponding wells of the capture plate coated with ACE-2 receptor. The plate was sealed  
116 and incubated at 37°C for 30 min followed removing mixtures and washing with 1X wash  
117 solution four times. Residual liquid was emptied by tapping dry. 100ul of TMB solution was  
118 added to each well, the plate was wrapped with aluminium foil and incubated in the dark at  
119 room temperature for 15 minutes. The reaction was quenched by adding 50ul of stop solution.  
120 The absorbance was read at 450nm (OD<sub>450</sub>) in an ELISA microplate reader. Percentage  
121 inhibition was calculated by  $(1 - \text{OD}_{450} \text{ value of sample} / \text{OD}_{450} \text{ value of negative control})$   
122 multiplied by 100%.

123

124 The Plaque Reduction Neutralization Test (PRNT) was performed in duplicate using 24-well  
125 tissue culture plates (TPP Techno Plastic Products AG, Trasadingen, Switzerland) in a  
126 biosafety level 3 facility using Vero E6 TMRESS2 cells [12] for the ancestral strain and

127 Omicron BA.2 as previously described [13]. All sera were heat-inactivated at 56°C for 30  
128 min before testing. Serial two-fold dilutions from 1:10 to 1:320 of each serum sample were  
129 incubated with 30–40 plaque-forming units of virus for 1 hour at 37°C and the mixture was  
130 added onto pre-formed cell monolayers. The culture plate was incubated for 1 hour at 37°C in  
131 a 5% CO<sub>2</sub> incubator. The virus-antibody inoculum was then discarded, and the cell  
132 monolayer was overlaid with 1% agarose in cell culture medium. The plates were fixed and  
133 stained after 3 days incubation. Antibody titres were defined as the reciprocal of the highest  
134 serum dilution that resulted in  $\geq 50\%$  reduction in the number of virus plaques (PRNT<sub>50</sub>). The  
135 average plaque numbers were calculated from the duplicates. Virus back titrations, positive  
136 and negative control sera were included in every experiment.

137

### 138 *Statistical analysis*

139 We analyzed data on antibody titers measured by the assays listed above at Day 0, Day 28  
140 and Day 182. We determined whether participants reported a laboratory-confirmed infection  
141 between Day 28 and Day 182, or had chosen to receive a fourth dose of a COVID-19 vaccine  
142 during the same period, and classified accordingly for analysis. We estimated group means  
143 for the ELISA and surrogate neutralizing percentages, and geometric mean titers for the live  
144 virus neutralization titers. We estimated the rate of waning in neutralizing antibody titers for  
145 those who were not infected and did not receive a fourth dose assuming an exponential rate of  
146 decline (constant decline on the logarithmic scale). Statistical analyses were conducted using  
147 R version 3.6.2 (R Foundation for Statistical Computing, Vienna, Austria).

148

## 149 **RESULTS**

150 We administered BNT162b2 as a third dose of COVID-19 vaccination to 314 participants  
151 between 18 October and 28 December 2021. We collected Day 28 samples from 312 (99%)

152 of these participants, and we collected Day 182 samples from 284 (90%) participants between  
153 20 April and 1 June 2022. The median time between receipt of BNT162b2 and collection of  
154 the Day 182 sample was 181 days (range 154, 210 days).

155

156 Further analyses focus on the 284 participants who provided a Day 182 sample. Among these  
157 284 participants, 279 (98%) had received two initial doses of CoronaVac and the remainder  
158 received two doses of BIBP. The median delay between the second dose of inactivated  
159 vaccination and the third dose of BNT162b2 administered in our study was 205 days (range  
160 94, 267 days). The median age was 53 years, 29% of participants were  $\geq 60$  years of age, 38%  
161 were female, and 93 (32%) had a chronic medical condition.

162

163 Among the 284 participants, 42 (15%) reported a COVID-19 infection between receipt of the  
164 third dose and collection of the Day 182 sample, and 21 (7.0%) reported receipt of a fourth  
165 dose prior to collection of the Day 182 sample including one participant who was infected as  
166 well as then receiving a fourth dose. The median delay from infection to collection of the Day  
167 182 sample was 55 days (range 10, 85 days). The median delay from the fourth dose to  
168 collection of the Day 182 sample was 19 days (range 7, 26) and 19 participants received  
169 BNT162b2 as a fourth dose while two received CoronaVac.

170

171 The third dose of BNT162b2 led to substantial increases in ELISA (Figure 1A) and surrogate  
172 virus neutralization levels (Figure 1B) at Day 28, which waned somewhat by Day 182 but  
173 still remained substantially higher than the levels at Day 0. ELISA values at Day 182 were  
174 statistically significantly higher in the small number of participants who were infected  
175 ( $p < 0.001$ , t-test) or received a fourth dose ( $p = 0.005$ , t-test) prior to Day 182. The sVNT  
176 responses were very high at Day 182 in all groups, but also statistically significantly higher in



177 the small number of participants who were infected ( $p=0.002$ , t-test) or received a fourth dose  
178 ( $p=0.032$ , t-test) prior to Day 182. There was no statistically significant difference in ELISA  
179 or sVNT levels by age at Day 182.

180

181 We measured PRNT<sub>50</sub> titers against the ancestral strain (Figure 1C) and Omicron BA.2  
182 (Figure 1D) in a subset of 39 participants at Day 0, 28 and 182. In the statistical comparisons  
183 within this subset that follow we exclude (because of the small sample sizes) from Day 182  
184 calculations the three infected participants and the two who received a fourth dose, although  
185 they are included in Figure 1 for completeness. At Day 28 and Day 182 the geometric mean  
186 PRNT<sub>50</sub> titers against the ancestral strain were 338 and 112, respectively. The corresponding  
187 geometric mean PRNT<sub>50</sub> titers against BA.2 were 55 and 14, respectively. There was no  
188 significant difference by age in PRNT<sub>50</sub> titers against the ancestral strain or BA.2 at Day 182.  
189 Assuming an exponential rate of waning from Day 28 to Day 182, we estimated that antibody  
190 titers would drop by half in 96 days for the ancestral strain and 79 days for BA.2.

191

192 Among the 42 infections, 30 (71%) occurred during the month of March 2022, with nine in  
193 February and three in April, when BA.2 predominated in the community. We did not find any  
194 statistically significant effects on the risk of laboratory-confirmed infection of the timing of  
195 third dose, age, sex, chronic conditions, or antibody measures at Day 28 (all  $p>0.05$ ,  
196 proportional hazards regression).

197

## 198 **DISCUSSION**

199 We show durable antibody responses to the ancestral strain six months after the third dose of  
200 BNT162b2 (Figure 1), consistent with other studies that show a strong and sustained antibody  
201 response to a third dose of BNT162b2 after two doses of BNT162b2 [14, 15] or after two

202 doses of inactivated vaccination [16]. Antibody titers measured by sVNT against the  
203 ancestral strain were higher at 97% six months after the third dose of BNT162b2 (and two  
204 earlier doses of CoronaVac) than six months after either two doses of BNT162b2 or two  
205 doses of CoronaVac, when sVNT inhibition had fallen to 80% and 20% respectively in  
206 another study [17]. However, neutralizing titers to Omicron BA.2 only reached a moderate  
207 geometric mean titer of 55 after the third dose, above a threshold thought to provide some  
208 degree of protection against infection in this assay [13] but titers had fallen to below a  
209 geometric mean of 14 within six months, likely below the protective threshold (Figure 1D).

210

211 There is some evidence from observational studies that third doses can protect against  
212 symptomatic Omicron BA.2 infection [1, 2]. In a study of the effectiveness of two and three  
213 doses of COVID-19 vaccines in Hong Kong we found evidence suggestive of a moderate  
214 level of protection against mild infection [18]. The immune mechanisms contributing to that  
215 protection are not fully elucidated but neutralizing antibodies are likely to play a major role,  
216 while cellular immunity may also contribute [19]. Fourth doses did improve antibody levels  
217 against the ancestral strain (Figure 1) and likely also against BA.2. From a small number of  
218 participants we observed that natural infection or (fourth dose) vaccination after third dose  
219 BNT162b2 vaccination generated similar antibody levels against ancestral virus, but infection  
220 generated higher antibody level against Omicron BA.2 than vaccination, suggesting a  
221 potential advantage in the breadth of antibody response from hybrid immunity [20]. Further  
222 studies are needed to confirm this finding and to determine the optimal timing of fourth doses  
223 under different types of prior immunity.

224

225 Our study had a number of limitations. A large wave of Omicron BA.2 occurred in Hong  
226 Kong in February-April 2022 with more than 1 million confirmed cases (14% of the

227 population) and 9000 deaths (1.2 deaths per 1000 persons) [21]. Many infections likely were  
228 undocumented. While 15% of our cohort reported an infection, including some infections that  
229 may not have been documented in the official case count, some other participants may have  
230 had an unrecognized infection, biasing upwards the antibody titers at Day 182.

231

232 In conclusion, a third dose of BNT162b2 provided a strong and durable immune response in  
233 adults who had previously received two doses of inactivated COVID-19 vaccine. Further  
234 research is needed on the value of immunogenicity data (including cellular immunity  
235 measures as well as antibody levels) to predict the clinical effectiveness of booster doses  
236 against symptomatic disease and severe disease with Omicron subvariants.

237

238

239 **ACKNOWLEDGEMENTS**

240 We gratefully acknowledge colleagues including Zacary Chai, Sara Chaothai, Kelvin Kwan,  
241 Yvonne Ng, Teresa So and Eileen Yu for technical support in preparing and conducting this  
242 study; Anson Ho for setting up the database; Julie Au and Lilly Wang for administrative  
243 support; Hetti Cheung, Victoria Wong, Bobo Yeung at HKU Health System; Cindy Man and  
244 other colleagues at the HKU Community Vaccination Centres at Gleneagles Hospital; and all  
245 the study participants for facilitating the study.

246

247 **FUNDING**

248 This project was supported by the Theme-based Research Scheme T11-705/21-N of the  
249 Research Grants Council of the Hong Kong Special Administrative Region, China (BJC).  
250 BJC is supported by a RGC Senior Research Fellow Scheme grant (HKU SRFS2021-7S03)  
251 from the Research Grants Council of the Hong Kong Special Administrative Region, China.  
252 The funding bodies had no role in the design of the study, the collection, analysis, and  
253 interpretation of data, or writing of the manuscript.

254

255 **AUTHOR CONTRIBUTIONS**

256 All authors meet the ICMJE criteria for authorship. Each author's contributions to the paper  
257 are listed below according to the CRediT model:

258 Conceptualization: BJC, GML, NHLL

259 Methodology: BJC, SMSC

260 Formal analysis: BJC, MM-S

261 Investigation: NYMA, KCKC, JKCL, LLHL

262 Funding acquisition: BJC

263 Project administration: BJC, SMSC, JSMP, NHLL

264 Supervision: BJC, SMSC, DKMI, LLMP, GML, JSMP, NHLL

265 Writing – original draft: BJC

266 Writing – review & editing: BJC, SMSC, MM-S, NYMA, KCKC, JKCL, LLHL, DKMI,

267 LLMP, GML, JSMP, NHLL.

268

269 **COMPETING INTERESTS**

270 BJC consults for AstraZeneca, Fosun Pharma, GlaxoSmithKline, Moderna, Pfizer, Roche and

271 Sanofi Pasteur. BJC has received research funding from Fosun Pharma. The authors report no

272 other potential conflicts of interest.

273

274 **REFERENCES**

- 275 1. Andrews N, Stowe J, Kirsebom F, et al. Covid-19 Vaccine Effectiveness against the  
276 Omicron (B.1.1.529) Variant. *N Engl J Med* **2022**; 386:1532-46.
- 277 2. Chemaitelly H, Ayoub HH, AlMukdad S, et al. Duration of mRNA vaccine protection  
278 against SARS-CoV-2 Omicron BA.1 and BA.2 subvariants in Qatar. *Nat Commun* **2022**;  
279 13:3082.
- 280 3. Barda N, Dagan N, Cohen C, et al. Effectiveness of a third dose of the BNT162b2 mRNA  
281 COVID-19 vaccine for preventing severe outcomes in Israel: an observational study. *Lancet*  
282 **2021**; 398:2093-100.
- 283 4. Ferdinands JM, Rao S, Dixon BE, et al. Waning 2-Dose and 3-Dose Effectiveness of  
284 mRNA Vaccines Against COVID-19-Associated Emergency Department and Urgent Care  
285 Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron  
286 Variant Predominance - VISION Network, 10 States, August 2021-January 2022. *MMWR*  
287 *Morb Mortal Wkly Rep* **2022**; 71:255-63.
- 288 5. Patalon T, Saciuk Y, Peretz A, et al. Waning effectiveness of the third dose of the  
289 BNT162b2 mRNA COVID-19 vaccine. *Nat Commun* **2022**; 13:3203.
- 290 6. Bar-On YM, Goldberg Y, Mandel M, et al. Protection by a Fourth Dose of BNT162b2  
291 against Omicron in Israel. *N Engl J Med* **2022**; 386:1712-20.
- 292 7. Grewal R, Kitchen SA, Nguyen L, et al. Effectiveness of a fourth dose of covid-19 mRNA  
293 vaccine against the omicron variant among long term care residents in Ontario, Canada: test  
294 negative design study. *BMJ* **2022**; 378:e071502.
- 295 8. Leung NHL, Cheng SMS, Martin-Sanchez M, et al. Immunogenicity of a third dose of  
296 BNT162b2 to ancestral SARS-CoV-2 & Omicron variant in adults who received two doses of  
297 inactivated vaccine. *Clin Infect Dis* **2022**.




- 298 9. Cheng SMS, Mok CKP, Leung YWY, et al. Neutralizing antibodies against the SARS-  
299 CoV-2 Omicron variant BA.1 following homologous and heterologous CoronaVac or  
300 BNT162b2 vaccination. *Nat Med* **2022**; 28:486-9.
- 301 10. Campos GRF, Almeida NBF, Filgueiras PS, et al. Booster dose of BNT162b2 after two  
302 doses of CoronaVac improves neutralization of SARS-CoV-2 Omicron variant. *Commun*  
303 *Med (Lond)* **2022**; 2:76.
- 304 11. Perera RAPM, Mok CKP, Tsang OTY, et al. Serological assays for SARS-CoV-2.  
305 *Eurosurveillance* **2020 (in press)**.
- 306 12. Matsuyama S, Nao N, Shirato K, et al. Enhanced isolation of SARS-CoV-2 by  
307 TMPRSS2-expressing cells. *Proc Natl Acad Sci U S A* **2020**; 117:7001-3.
- 308 13. Lau EH, Hui DS, Tsang OT, et al. Long-term persistence of SARS-CoV-2 neutralizing  
309 antibody responses after infection and estimates of the duration of protection.  
310 *EClinicalMedicine* **2021**; 41:101174.
- 311 14. Gilboa M, Regev-Yochay G, Mandelboim M, et al. Durability of the immune response to  
312 a third BNT162b2 dose; five months follow-up. *medRxiv* **2022**:doi:  
313 10.1101/2022.05.03.22274592.
- 314 15. Eliakim-Raz N, Stemmer A, Leibovici-Weisman Y, et al. Durability of response to the  
315 third dose of the SARS-CoV-2 BNT162b2 vaccine in adults aged 60 years and older: Three-  
316 month follow-up. *medRxiv* **2022**:doi: 10.1101/2021.12.25.21268336.
- 317 16. Silva ARD, Jr., Villas-Boas LS, Paula AV, et al. Neutralizing antibodies against the  
318 SARS-CoV-2 Omicron variant following two CoronaVac vaccinations and a  
319 Pfizer/BioNTech mRNA vaccine booster. *Rev Inst Med Trop Sao Paulo* **2022**; 64:e43.
- 320 17. Cowling BJ, Wong IOL, Shiu EYC, et al. Strength and durability of antibody responses to  
321 BNT162b2 and CoronaVac. *Vaccine* **2022**.

- 322 18. McMenamin ME, Nealon J, Lin Y, et al. Vaccine effectiveness of two and three doses of  
323 BNT162b2 and CoronaVac against COVID-19 in Hong Kong. *Lancet Infect Dis* **2022**.
- 324 19. Kent SJ, Khoury DS, Reynaldi A, et al. Disentangling the relative importance of T cell  
325 responses in COVID-19: leading actors or supporting cast? *Nat Rev Immunol* **2022**; 22:387-  
326 97.
- 327 20. Epsi NJ, Richard SA, Lindholm DA, et al. Understanding 'hybrid immunity': comparison  
328 and predictors of humoral immune responses to SARS-CoV-2 infection and COVID-19  
329 vaccines. *Clin Infect Dis* **2022**.
- 330 21. Mefsin Y, Chen D, Bond HS, et al. Epidemiology of infections with SARS-CoV-2  
331 Omicron BA.2 variant in Hong Kong, January-March 2022. *medRxiv*  
332 **2022:2022.04.07.22273595**.
- 333
- 334
- 335



336 **FIGURE LEGEND**

337 Figure 1. Antibody titers measured prior to receipt of a third dose of BNT162b2 (Day 0), and  
338 at Day 28 and Day 182 following that dose, using four assays. Samples collected at Day 182  
339 were stratified by whether the participant had been infected or received a fourth dose between  
340 Day 28 and Day 182. Panel A: antibody titers measured by an ELISA assay for serum IgG  
341 against the receptor binding domain (RBD) of the spike protein of the ancestral strain, with X  
342 indicating the median level. Panel B: Responses to a surrogate virus neutralization test (sVNT)  
343 against the ancestral strain, with X indicating the median level. Panel C: Live virus plaque  
344 reduction neutralization test (PRNT) against ancestral strain with endpoints at 50% (PRNT<sub>50</sub>)  
345 with X indicating the geometric mean titer in each group. Panel D: Live virus PRNT<sub>50</sub> against  
346 the Omicron BA.2 subvariant, with X indicating the geometric mean titer in each group. In  
347 panels C and D, antibody titers measured at <10 are plotted at 5 on the y-axis.  
348

**A.****RBD ELISA IgG****B.****Surrogate VNT****C.****Ancestral strain PRNT****D.****BA.2 PRNT**